Study: INCB 18424-312 A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.